The Lancet Neurology in conversation with
Aug 12, 2026 · 17 min · 12 segments
For decades, a diagnosis of vanishing white matter disease came with no real treatment — so how is an old blood-pressure pill offering hope? In this episode of In Conversation With…The Lancet…
Marjo van der KnaapGuest
Laura HartHost
Okay, so you briefly mentioned, um, the stress response there, and if I understand correctly, the integrated stress response, also known as ISR, is central to vanishing white matter disease pathophysiology.

So could you explain what this ISR is, um, how it goes wrong in the disease, and why it took time for researchers to recognize it as a druggable target?

Well, vanishing white matter is caused by, uh, mutations in the genes that encode eukaryotic initiation factor 2B, so eIF2B.

Cells have the ISR to cope with stresses like elevated temperature, misfolded proteins, viral infections, and one of the first steps of the ISR consists of inhibition of eIF2B activity, which then triggers the downstream response with a multitude of stress proteins that either lead to repair or apoptosis of the cell.

In vanishing white matter, mutant eIF2B has a decreased activity, so the downstream ISR is always activated, and it's the constitutive activation of the ISR that drives vanishing white matter.

And then why the brain white matter is selectively vulnerable, that's something that we really don't know.

eIF2B is also conditional for the translation of every mRNA into protein and regulates the general rate of protein synthesis.

And that makes you realize that in vanishing white matter, mutant eIF2B always has remaining activity.

Protein synthesis is normal in vanishing white matter, so apparently the remaining eIF2B activity is sufficient to guarantee protein synthesis.


And it's through the mutant mice that we made, we made mutant mice that have vanishing white matter.

It's through those mice that I understood that targeting eIF2B and the ISR was certainly possible.

Okay, so you briefly mentioned, um, the stress response there, and if I understand correctly, the integrated stress response, also known as ISR, is central to vanishing white matter disease pathophysiology.

So could you explain what this ISR is, um, how it goes wrong in the disease, and why it took time for researchers to recognize it as a druggable target?

Well, vanishing white matter is caused by, uh, mutations in the genes that encode eukaryotic initiation factor 2B, so eIF2B.

Cells have the ISR to cope with stresses like elevated temperature, misfolded proteins, viral infections, and one of the first steps of the ISR consists of inhibition of eIF2B activity, which then triggers the downstream response with a multitude of stress proteins that either lead to repair or apoptosis of the cell.

In vanishing white matter, mutant eIF2B has a decreased activity, so the downstream ISR is always activated, and it's the constitutive activation of the ISR that drives vanishing white matter.

And then why the brain white matter is selectively vulnerable, that's something that we really don't know.

eIF2B is also conditional for the translation of every mRNA into protein and regulates the general rate of protein synthesis.

And that makes you realize that in vanishing white matter, mutant eIF2B always has remaining activity.

Protein synthesis is normal in vanishing white matter, so apparently the remaining eIF2B activity is sufficient to guarantee protein synthesis.


And it's through the mutant mice that we made, we made mutant mice that have vanishing white matter.

It's through those mice that I understood that targeting eIF2B and the ISR was certainly possible.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.